Jun 27 |
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
|
Jun 25 |
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
|
Jun 6 |
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
|
Jun 3 |
Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
|
May 28 |
Ensysce Biosciences regains Nasdaq compliance
|
May 28 |
Ensysce Biosciences Regains Compliance with Nasdaq
|
May 20 |
Sector Update: Health Care Stocks Softer Late Afternoon
|
May 20 |
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
|
May 14 |
Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 13 |
Ensysce Biosciences GAAP EPS of -$0.55
|